LeMaitre Vascular, Inc. (LMAT)
| Market Cap | 2.56B |
| Revenue (ttm) | 249.60M |
| Net Income (ttm) | 57.73M |
| Shares Out | 22.85M |
| EPS (ttm) | 2.52 |
| PE Ratio | 45.44 |
| Forward PE | 39.43 |
| Dividend | $1.00 (0.87%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 135,351 |
| Open | 113.23 |
| Previous Close | 114.52 |
| Day's Range | 111.68 - 113.26 |
| 52-Week Range | 78.01 - 118.01 |
| Beta | 0.67 |
| Analysts | Buy |
| Price Target | 105.80 (-5.75%) |
| Earnings Date | May 5, 2026 |
About LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter... [Read more]
Financial Performance
In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $105.8, which is a decrease of -5.75% from the latest price.
News
LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after...
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thu...
LeMaitre to Participate at Upcoming Investor Conferences in March
BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.
LeMaitre Vascular Earnings Call Transcript: Q4 2025
Q4 2025 saw 16% sales growth, 71.7% gross margin, and 47% operating income growth, with strong international expansion and product launches. 2026 guidance projects 12% sales growth, 21% adjusted operating income growth, and continued margin expansion.
LeMaitre Q4 2025 Financial Results
BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarter...
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 202...
Final Trade: LMAT, REGN, BA, TJX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LeMaitre Vascular Earnings Call Transcript: Q3 2025
Q3 delivered 12% organic growth, record margins, and strong cash flow, with biologics and international launches outperforming expectations. Full-year guidance was raised for revenue, operating income, and EPS, despite headwinds from a catheter recall and FX.
LeMaitre Q3 2025 Financial Results
BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarter...
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, ...
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.
LeMaitre Vascular Earnings Call Transcript: Q2 2025
Q2 2025 saw 15% sales growth, 70% gross margin, and 16% EPS growth, with strong performance in catheters, grafts, and international markets. Full-year guidance was raised across all key metrics, and new product launches and regulatory progress are expected to drive continued growth.
LeMaitre Q2 2025 Financial Results
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarter...
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, af...
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare ...
LeMaitre Vascular Earnings Call Transcript: Q1 2025
Q1 2025 saw 13% organic sales growth, record results across all product lines, and a raised 2025 sales guidance to $245 million. Gross margin improved to 69.2%, and the company expanded its sales force and direct international presence, with Artegraft's European launch imminent.
LeMaitre Q1 2025 Financial Results
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterl...
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025
BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, afte...
LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tue...
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors
GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ae...
LeMaitre Vascular Earnings Call Transcript: Q4 2024
Q4 2024 saw 14% sales growth, 26% higher operating income, and 30% EPS growth, driven by strong product and geographic performance. 2025 guidance calls for 10% organic sales growth, 69.7% gross margin, and continued sales force expansion, with new product launches and regulatory milestones expected.
LeMaitre Q4 2024 Financial Results
BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend...
LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025...